The “Global TIL-based Therapy Market (2nd Edition), 2023-2035” report features an extensive study of the current market landscape and future potential of TIL-based therapies over the next decade.
Key Inclusions
- An executive summary of the insights captured during our research. It offers a high-level view on the current state of globalTIL therapies market and its likely evolution in the mid-long term.
- A general overview of TIL-based therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in the development of TIL-based therapies.
- A detailed assessment of the overall market landscape of TIL-based therapies, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target indication (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer, squamous cell carcinoma, fallopian tube cancer, gastric cancer, head and neck squamous cell carcinoma and others), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dosing frequency (single dose and multiple dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this domain.
- An analysis of completed, ongoing, and planned clinical studies related to TIL-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, study design, most active players (in terms of number of registered trials), key focus areas and geography.
- An insightful analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TIL-based therapies, considering them to be KOLs, who are actively involved in R&D of TIL-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
- Elaborate profiles of mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
- A detailed analysis of recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), manufacturing agreements, clinical trial collaborations and others.
- An analysis of the funding and investments that have been made into companies having proprietary TIL-based products / technologies, including venture capital financing, capital raised from Initial Public Offerings (IPOs) and subsequent offerings, grants, and debt financing.
- An in-depth analysis of patents related to TIL-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted and patent applications), patent publication year, geographical distribution, type of player, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading players (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.
- A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
- An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TIL-based therapy that is likely to be marketed in the coming years.
- Elaborate profiles of the leading players in the domain of TIL-based therapies. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TIL-based therapies, the technology portfolio (if available), recent developments related to TIL-based therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
- Target Indication(s)
- Cellectis
- Cellular Biomedicine Group
- Iovance Biotherapeutics
- Lytix Biopharma
- Phio Pharmaceuticals
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
Key Questions Answered
- What is the growth rate of TIL-based therapy market?
- Which region has the highest growth rate in the TIL-based Therapies market?
- How many players are developing TIL-based Therapies?
- Which target indication covers the largest TIL-based therapy market share?
- What is the partnership and collaboration trend in the TIL-based therapy domain?
- What is the current IP landscape of TIL-based therapies market?
To view more details on this report, click on the link
You may also be interested in the following titles:
| Medical Device Coatings and Surface Modification Technologies Market |
| mRNA Synthesis and Manufacturing Services Market |
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415